Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Leases (2022 - 2025)

Dianthus Therapeutics has reported Operating Leases over the past 4 years, most recently at $1.1 million for Q3 2025.

  • Quarterly results put Operating Leases at $1.1 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $1.1 million (changed N/A YoY), and the annual figure for FY2024 was $1.2 million, up 597.02%.
  • Operating Leases for Q3 2025 was $1.1 million at Dianthus Therapeutics, down from $1.1 million in the prior quarter.
  • Over the last five years, Operating Leases for DNTH hit a ceiling of $29.1 million in Q1 2022 and a floor of $30000.0 in Q2 2024.
  • Median Operating Leases over the past 4 years was $1.1 million (2025), compared with a mean of $7.5 million.
  • Biggest five-year swings in Operating Leases: tumbled 99.05% in 2023 and later soared 3630.0% in 2025.
  • Dianthus Therapeutics' Operating Leases stood at $438000.0 in 2022, then crashed by 61.64% to $168000.0 in 2023, then soared by 597.02% to $1.2 million in 2024, then decreased by 8.8% to $1.1 million in 2025.
  • The last three reported values for Operating Leases were $1.1 million (Q3 2025), $1.1 million (Q2 2025), and $1.2 million (Q1 2025) per Business Quant data.